Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

Guzauskas GF, Basu A, Carlson JJ, Veenstra DL.

Value Health. 2019 Sep;22(9):988-994. doi: 10.1016/j.jval.2019.03.023. Epub 2019 Aug 1.

PMID:
31511188
2.

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study.

Regier DA, Veenstra DL, Basu A, Carlson JJ.

Pharmacoeconomics. 2019 Sep 6. doi: 10.1007/s40273-019-00834-0. [Epub ahead of print]

PMID:
31489595
3.

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.

Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA.

Pharmacoeconomics. 2019 Sep 5. doi: 10.1007/s40273-019-00832-2. [Epub ahead of print]

PMID:
31485925
4.

Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study.

Niu X, Amendola LM, Hart R, Bennette CS, Heagerty P, Horike-Pyne M, Trinidad SB, Rosenthal EA, Comstock B, Nefcy C, Hisama FM, Bennett RL, Grady WM, Gallego CJ, Tarczy-Hornoch P, Fullerton SM, Burke W, Regier DA, Dorschner MO, Shirts BH, Robertson PD, Nickerson DA, Patrick DL, Jarvik GP, Veenstra DL.

Contemp Clin Trials. 2019 Sep;84:105820. doi: 10.1016/j.cct.2019.105820. Epub 2019 Aug 7.

PMID:
31400517
5.

Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration.

Bounthavong M, Devine EB, Christopher MLD, Harvey MA, Veenstra DL, Basu A.

Health Serv Res. 2019 Oct;54(5):1055-1064. doi: 10.1111/1475-6773.13194. Epub 2019 Jul 17.

PMID:
31313839
6.

Cost-effectiveness of population genomic screening.

Veenstra DL, Guzauskas G, Peterson J, Hassen DA, Snyder S, Hao J, Williams M.

Genet Med. 2019 Jul 15. doi: 10.1038/s41436-019-0580-4. [Epub ahead of print] No abstract available.

PMID:
31303645
7.

How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.

Li M, Basu A, Bennette C, Veenstra D, Garrison LP Jr.

Value Health. 2019 Jul;22(7):777-784. doi: 10.1016/j.jval.2019.02.002. Epub 2019 May 17.

PMID:
31277824
8.

Do cancer treatments have option value? Real-world evidence from metastatic melanoma.

Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP.

Health Econ. 2019 Jul;28(7):855-867. doi: 10.1002/hec.3899.

PMID:
31237095
9.

Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies.

Robinson JO, Wynn J, Biesecker B, Biesecker LG, Bernhardt B, Brothers KB, Chung WK, Christensen KD, Green RC, McGuire AL, Hart MR, Griesemer I, Patrick DL, Rini C, Veenstra D, Cronin AM, Gray SW.

Genet Med. 2019 Jun 13. doi: 10.1038/s41436-019-0565-3. [Epub ahead of print]

PMID:
31189963
10.

Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.

Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL.

Pharmacoeconomics. 2019 Aug;37(8):1071. doi: 10.1007/s40273-019-00809-1.

PMID:
31089966
11.

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation.

Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL.

J Genet Couns. 2019 Apr;28(2):477-490. doi: 10.1007/s10897-018-0286-9. Epub 2018 Dec 14.

PMID:
30964586
12.

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People.

Henderson LM, Robinson RF, Ray L, Khan BA, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL.

Clin Transl Sci. 2019 May;12(3):312-320. doi: 10.1111/cts.12611. Epub 2019 Mar 1.

13.

Correction: Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study.

Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, Biswas S, Bowling KM, Brothers KB, Conlin LK, Cooper GM, Dulik MC, East KM, Everett JN, Finnila CR, Ghazani AA, Gilmore MJ, Goddard KAB, Jarvik GP, Johnston JJ, Kauffman TL, Kelley WV, Krier JB, Lewis KL, McGuire AL, McMullen C, Ou J, Plon SE, Rehm HL, Richards CS, Romasko EJ, Sagardia AM, Spinner NB, Thompson ML, Turbitt E, Vassy JL, Wilfond BS, Veenstra DL, Berg JS, Green RC, Biesecker LG, Hindorff LA.

Genet Med. 2019 May;21(5):1261-1262. doi: 10.1038/s41436-019-0440-2.

PMID:
30670880
14.

Group schema-focused therapy enriched with psychomotor therapy versus treatment as usual for older adults with cluster B and/or C personality disorders: a randomized trial.

van Dijk SDM, Veenstra MS, Bouman R, Peekel J, Veenstra DH, van Dalen PJ, van Asselt ADI, Boshuisen ML, van Alphen SPJ, van den Brink RHS, Oude Voshaar RC.

BMC Psychiatry. 2019 Jan 15;19(1):26. doi: 10.1186/s12888-018-2004-4.

15.

How can clinical researchers quantify the value of their proposed comparative research?

Basu A, Veenstra DL, Carlson JJ, Wang WJ, Branch K, Probstfield J.

Am Heart J. 2019 Mar;209:116-125. doi: 10.1016/j.ahj.2018.12.003. Epub 2018 Dec 8. No abstract available.

PMID:
30638543
16.

Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.

Guzauskas GF, Masaquel A, Thuresson PO, Dawson K, Veenstra DL.

Leuk Lymphoma. 2019 Jul;60(7):1668-1676. doi: 10.1080/10428194.2018.1551532. Epub 2019 Jan 11.

PMID:
30632837
17.

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.

Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL.

J Manag Care Spec Pharm. 2018 Dec;24(12):1210-1217. doi: 10.18553/jmcp.2018.24.12.1210.

18.

Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study.

Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, Biswas S, Bowling KM, Brothers KB, Conlin LK, Cooper GM, Dulik MC, East KM, Everett JN, Finnila CR, Ghazani AA, Gilmore MJ, Goddard KAB, Jarvik GP, Johnston JJ, Kauffman TL, Kelley WV, Krier JB, Lewis KL, McGuire AL, McMullen C, Ou J, Plon SE, Rehm HL, Richards CS, Romasko EJ, Miren Sagardia A, Spinner NB, Thompson ML, Turbitt E, Vassy JL, Wilfond BS, Veenstra DL, Berg JS, Green RC, Biesecker LG, Hindorff LA.

Genet Med. 2019 May;21(5):1100-1110. doi: 10.1038/s41436-018-0308-x. Epub 2018 Oct 5. Erratum in: Genet Med. 2019 Jan 22;:.

PMID:
30287922
19.

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.

Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL.

Pharmacoeconomics. 2018 Dec;36(12):1463-1473. doi: 10.1007/s40273-018-0709-3. Erratum in: Pharmacoeconomics. 2019 May 14;:.

20.

The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations.

Amendola LM, Berg JS, Horowitz CR, Angelo F, Bensen JT, Biesecker BB, Biesecker LG, Cooper GM, East K, Filipski K, Fullerton SM, Gelb BD, Goddard KAB, Hailu B, Hart R, Hassmiller-Lich K, Joseph G, Kenny EE, Koenig BA, Knight S, Kwok PY, Lewis KL, McGuire AL, Norton ME, Ou J, Parsons DW, Powell BC, Risch N, Robinson M, Rini C, Scollon S, Slavotinek AM, Veenstra DL, Wasserstein MP, Wilfond BS, Hindorff LA; CSER consortium, Plon SE, Jarvik GP.

Am J Hum Genet. 2018 Sep 6;103(3):319-327. doi: 10.1016/j.ajhg.2018.08.007.

21.

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation.

Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL.

J Genet Couns. 2018 Sep 1. doi: 10.1007/s10897-018-0286-9. [Epub ahead of print]

PMID:
30173308
22.

Considerations in initiating genomic screening programs in health care systems.

Williams JK, Feero WG, Veenstra DL, Starkweather A, Cashion AK.

Nurs Outlook. 2018 Nov;66(6):570-575. doi: 10.1016/j.outlook.2018.06.008. Epub 2018 Jul 11. No abstract available.

PMID:
30093136
23.

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.

Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD.

Cancer Med. 2018 Sep;7(9):4251-4260. doi: 10.1002/cam4.1657. Epub 2018 Jul 20.

24.

Harmonizing Outcomes for Genomic Medicine: Comparison of eMERGE Outcomes to ClinGen Outcome/Intervention Pairs.

Williams JL, Chung WK, Fedotov A, Kiryluk K, Weng C, Connolly JJ, Harr M, Hakonarson H, Leppig KA, Larson EB, Jarvik GP, Veenstra DL, Hoell C, Smith ME, Holm IA, Peterson JF, Williams MS.

Healthcare (Basel). 2018 Jul 13;6(3). pii: E83. doi: 10.3390/healthcare6030083.

25.

Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.

Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL.

J Med Econ. 2018 Oct;21(10):960-967. doi: 10.1080/13696998.2018.1489254. Epub 2018 Jul 6.

PMID:
29898619
26.

Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment.

Weymann D, Veenstra DL, Jarvik GP, Regier DA.

Eur J Hum Genet. 2018 Sep;26(9):1257-1265. doi: 10.1038/s41431-018-0161-z. Epub 2018 May 25.

27.

Precision Medicine, Genome Sequencing, and Improved Population Health.

Feero WG, Wicklund CA, Veenstra D.

JAMA. 2018 May 15;319(19):1979-1980. doi: 10.1001/jama.2018.2925. No abstract available.

PMID:
29547675
28.

Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry.

Laurino MY, Truitt AR, Tenney L, Fisher D, Lindor NM, Veenstra D, Jarvik GP, Newcomb PA, Fullerton SM.

Mol Genet Genomic Med. 2017 Nov;5(6):700-708. doi: 10.1002/mgg3.328. Epub 2017 Aug 23.

29.

Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, Lertora JJL, Mahasirimongkol S, McLeod HL, Mockenhaupt M, Pacanowski M, Phillips EJ, Pinheiro S, Pirmohamed M, Sung C, Suwankesawong W, Trepanier L, Tumminia SJ, Veenstra D, Yuliwulandari R, Shear NH.

Clin Pharmacol Ther. 2018 Mar;103(3):390-394. doi: 10.1002/cpt.890. Epub 2017 Nov 6. Review.

30.

Financial benefit of a smoking cessation program prior to elective colorectal surgery.

Gaskill CE, Kling CE, Varghese TK Jr, Veenstra DL, Thirlby RC, Flum DR, Alfonso-Cristancho R.

J Surg Res. 2017 Jul;215:183-189. doi: 10.1016/j.jss.2017.03.067. Epub 2017 Apr 7.

31.

Dependency and health utilities in stroke: Data to inform cost-effectiveness analyses.

Ali M, MacIsaac R, Quinn TJ, Bath PM, Veenstra DL, Xu Y, Brady MC, Patel A, Lees KR.

Eur Stroke J. 2017 Mar;2(1):70-76. doi: 10.1177/2396987316683780. Epub 2017 Mar 1.

32.

Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.

Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL.

Clin Pharmacol Ther. 2017 Nov;102(5):805-814. doi: 10.1002/cpt.663. Epub 2017 Jul 10.

33.

What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?

Guzauskas GF, Chen E, Lalla D, Yu E, Tayama D, Veenstra DL.

Int J Stroke. 2017 Feb;12(2):137-144. doi: 10.1177/1747493016669887. Epub 2016 Oct 10.

PMID:
28134053
34.

The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.

Veenstra DL, Guzauskas GF, Villa KF, Boudreau DM.

J Med Econ. 2017 May;20(5):453-463. doi: 10.1080/13696998.2016.1275652. Epub 2017 Jan 7.

PMID:
28008770
35.

Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Guzauskas GF, Villa KF, Vanhove GF, Fisher VL, Veenstra DL.

J Adolesc Young Adult Oncol. 2017 Mar;6(1):53-61. doi: 10.1089/jayao.2016.0049. Epub 2016 Oct 25.

36.

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.

Hart R, Veenstra DL, Boudreau DM, Roth JA.

Am J Med. 2017 Feb;130(2):222-228. doi: 10.1016/j.amjmed.2016.08.017. Epub 2016 Sep 2.

37.

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.

Serbin MA, Guzauskas GF, Veenstra DL.

J Manag Care Spec Pharm. 2016 Aug;22(8):939-47. doi: 10.18553/jmcp.2016.22.8.939. Review.

38.

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.

Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH; CSER Consortium.

Am J Hum Genet. 2016 Jul 7;99(1):246. doi: 10.1016/j.ajhg.2016.06.002. No abstract available.

39.

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine.

Green RC, Goddard KAB, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH; CSER Consortium.

Am J Hum Genet. 2016 Jun 2;98(6):1051-1066. doi: 10.1016/j.ajhg.2016.04.011. Epub 2016 May 12. Erratum in: Am J Hum Genet. 2016 Jul 7;99(1):246.

40.

Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ.

Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24.

41.

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL.

J Natl Cancer Inst. 2015 Dec 29;108(2). pii: djv324. doi: 10.1093/jnci/djv324. Print 2016 Feb.

42.

Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome.

Gallego CJ, Perez ML, Burt A, Amendola LM, Shirts BH, Pritchard CC, Hisama FM, Bennett RL, Veenstra DL, Jarvik GP.

J Genet Couns. 2016 Jun;25(3):515-9. doi: 10.1007/s10897-015-9902-0. Epub 2015 Dec 5.

PMID:
26637299
43.
44.

A Framework for Prioritizing Research Investments in Precision Medicine.

Basu A, Carlson JJ, Veenstra DL.

Med Decis Making. 2016 Jul;36(5):567-80. doi: 10.1177/0272989X15610780. Epub 2015 Oct 26.

45.

Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT).

Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL.

J Manag Care Spec Pharm. 2015 Aug;21(8):700-12. Review.

46.

Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL.

J Clin Oncol. 2015 Jun 20;33(18):2084-91. doi: 10.1200/JCO.2014.59.3665. Epub 2015 May 4.

47.

Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.

Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D.

Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):619-27. doi: 10.1002/pds.3769. Epub 2015 Apr 8.

48.

Response to Phillips et al.

Bennette CS, Burke W, Jarvik GP, Veenstra DL.

Genet Med. 2015 Apr;17(4):315. doi: 10.1038/gim.2015.11. No abstract available.

PMID:
25835196
49.

Design, implementation, and first-year outcomes of a value-based drug formulary.

Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB.

J Manag Care Spec Pharm. 2015 Apr;21(4):269-75.

50.

Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment.

Regier DA, Peacock SJ, Pataky R, van der Hoek K, Jarvik GP, Hoch J, Veenstra D.

CMAJ. 2015 Apr 7;187(6):E190-E197. doi: 10.1503/cmaj.140697. Epub 2015 Mar 9.

Supplemental Content

Loading ...
Support Center